각막 교차 결합술 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Corneal Cross Linking Devices Market Summary

The global corneal cross linking devices market size was valued at USD 151.7 million in 2025 and is projected to grow from USD 163.5 million in 2026 to USD 279.4 million by 2033, at a CAGR of 8.0% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.4% in 2025. The global market is experiencing strong growth, driven by the increasing prevalence and diagnosis of keratoconus and other corneal ectatic disorders.

Greater awareness of early disease detection and the clinical benefits of corneal cross-linking are encouraging the adoption of these procedures. Technological advancements, including accelerated and epithelium-on cross-linking systems, are improving treatment efficiency and patient convenience. The market is also benefiting from the expansion of ophthalmic infrastructure and the increasing availability of specialized corneal care.

The corneal cross-linking devices industry is entering an important phase of development as rising awareness of keratoconus, improved diagnosis, and technological advances in cross-linking procedures expand the addressable patient population. Corneal cross-linking is primarily used to strengthen the cornea and slow or halt the progression of keratoconus, a progressive disorder characterized by thinning and weakening of the cornea. Unlike spectacles and contact lenses, which primarily correct the resulting visual impairment, CXL targets the underlying biomechanical instability of the cornea.

The market is particularly attractive because keratoconus frequently affects younger individuals, creating a substantial long-term clinical burden. A recent systematic review and meta-analysis published in Cornea estimated global keratoconus prevalence at 289.1 cases per 100,000 people, equivalent to approximately 0.24% of the population, and concluded that more than 23.7 million people globally are affected. The study also found that prevalence and incidence were highest among people aged 20-29 years and that prevalence was particularly high in South Asia, West Asia, and Africa.

The commercial opportunity therefore, extends beyond simply replacing existing UV-A systems. The introduction of epi-on therapy could increase patient willingness to undergo treatment, particularly among patients who may be reluctant to undergo epithelial removal. Reimbursement represents a major determinant of CXL adoption because treatment requires specialized equipment, trained ophthalmologists, and procedure-specific products.

The U.S. market has recently received an important reimbursement development. In April 2026, Glaukos announced that CMS had assigned a permanent HCPCS J-code, J2789, to Epioxa, effective July 1, 2026. The company stated that the product-specific code is expected to streamline reporting and payment and support market access initiatives. This development is important because regulatory approval alone does not guarantee commercial adoption. Physicians and facilities need a viable pathway for reimbursement, while patients need reasonable access to the treatment.

Global Corneal Cross Linking Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global corneal cross linking devices market report based on product, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• UVA Delivery Systems
• Riboflavin Solutions
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Keratoconus
• Pellucid Marginal Degeneration
• Ectasia Following Refractive Surgery
• Infectious Keratitis (PACK- CXL)
• Bullous Keratopathy
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Ophthalmology Clinics/ Eye Centers
• Ambulatory Surgery Centers
• Region Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Thailand
  • Australia
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in Middle East and Africa
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Corneal Cross Linking Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Corneal Cross Linking Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Corneal Cross Linking Devices Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Corneal Cross Linking Devices Market: Product Movement Analysis
• 4.3. Corneal Cross Linking Devices Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. UVA Delivery Systems
  • 4.5.1. UVA Delivery Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Riboflavin Solutions
  • 4.6.1. Riboflavin Solutions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Corneal Cross Linking Devices Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Corneal Cross Linking Devices Market: Application Movement Analysis
• 5.3. Corneal Cross Linking Devices Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Keratoconus
  • 5.5.1. Keratoconus Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Pellucid Marginal Degeneration
  • 5.6.1. Pellucid Marginal Degeneration Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Ectasia Following Refractive Surgery
  • 5.7.1. Ectasia Following Refractive Surgery Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Infectious Keratitis (PACK- CXL)
  • 5.8.1. Infectious Keratitis (PACK- CXL) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Bullous Keratopathy
  • 5.9.1. Bullous Keratopathy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Corneal Cross Linking Devices Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Corneal Cross Linking Devices Market: End Use Movement Analysis
• 6.3. Corneal Cross Linking Devices Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Hospitals
  • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Ophthalmology Clinics/ Eye Centers
  • 6.6.1. Ophthalmology Clinics/ Eye Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Ambulatory Surgery Centers
  • 6.7.1. Ambulatory Surgery Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Corneal Cross Linking Devices Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Corneal Cross Linking Devices Market Movement Analysis
• 7.3. Corneal Cross Linking Devices Market: Regional Estimates & Trend Analysis by Product & Source
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. North America
  • 7.5.1. North America Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. UK Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Germany Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. France Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. Italy Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Spain Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Denmark
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Denmark Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Reimbursement scenario
    • 7.6.8.5. Sweden Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.9. Norway
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Competitive Scenario
    • 7.6.9.3. Regulatory Framework
    • 7.6.9.4. Reimbursement scenario
    • 7.6.9.5. Norway Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Japan
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Japan Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. China Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. India Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. South Korea Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.6. Australia
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Australia Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Thailand Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. Brazil
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Brazil Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Argentina Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Middle East & Africa
  • 7.9.1. Middle East & Africa Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.2. South Africa
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. South Africa Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. Saudi Arabia Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Competitive Scenario
    • 7.9.4.3. Regulatory Framework
    • 7.9.4.4. Reimbursement scenario
    • 7.9.4.5. UAE Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Competitive Scenario
    • 7.9.5.3. Regulatory Framework
    • 7.9.5.4. Reimbursement scenario
    • 7.9.5.5. Kuwait Corneal Cross Linking Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. Glaukos Corporation
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Product Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. SCHWIND
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Product Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. Peschke Trade GmbH
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Product Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Micro Medical Devices
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Product Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. IROMED GROUP/ SERVImed Industrial
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Product Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Appasamy Associates
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Product Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. Ivis Technologies
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Product Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. Biotech Healthcare
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Product Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. Aurolab
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Product Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. Opto Eletronica SA
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Product Benchmarking
    • 8.2.10.4. Strategic Initiatives